Quiet today — no notable KOL discussion in the last 48 hours.
A practical treatment challenge is in focus for patients with HR+/HER2- metastatic breast cancer who are unable to swallow pills, limiting their options to IV chemotherapy over oral targeted therapies.
“Because she couldn’t swallow pills, oral targeted tx options for her HR+/HER2- MBC weren’t possible. She was limited to IV chemotherapy, &”
— @JaniceTNBCmets · Oral vs. IV Therapy Challenges · View post ↗📌 Amplified by @KolPulseAI
Surgical outcomes in colorectal cancer. A meta-analysis of 2,034 patients investigated whether perioperative serum sodium could predict intestinal anastomotic leaks, finding no significant overall association. Other topics included preclinical research on arginine biosynthesis in colorectal cancer cells and a review on esophageal peristalsis.
“Can perioperative serum sodium predict intestinal anastomotic leaks? Our meta-analysis of 2,034 patients found no significant overall association, despite suggestive findings in individual studies.”
— @KaiserSadiq · Colorectal Surgery Complications · View post ↗Track oncology’s top KOLs in your specialty
Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:
- ✓Enhanced KOL profiles
- ✓Pharma influence & potential advisory-board patterns
- ✓2025 Open Payments financial analysis
- ✓Social-media sentiment & trend signals
Quiet today — no notable KOL discussion in the last 48 hours.
Treatment optimization, with a key theme being that "More is not better," referencing the phase III ENDURANCE (E1A11) trial. Specific conversations include the role and sequencing of CELMoDs relative to BCMA-directed therapy, as well as ongoing refinement of treatment algorithms for smoldering and newly diagnosed multiple myeloma (NDMM), including maintenance and MRD assessment.
“Treatment Algorithm discussion on Smoldering Myeloma & NDMM w/ @GKaurMD”
— @OncBrothers · Treatment Algorithms · View post ↗
“I have this conversation with my patients with standard risk myeloma all the time and I am so glad to finally have an answer to them!”
— @tarekmd91 · Standard Risk Myeloma · View post ↗📌 Amplified by @KolPulseAI
A newly published phase 1 study of englumafusp alfa combined with the bispecific antibody glofitamab in B-NHL, highlighting the role of T-cell co-stimulation. Additionally, a new ASCO guideline on the use of circulating tumor DNA (ctDNA) testing in lymphoma is a key topic, alongside educational content on MDS diagnosis and risk stratification.
“Bispecific antibodies, like CARTs, require T-cell co-stimulation to achieve their full potential.”
— @DocHutchings · Bispecific antibody mechanism · View post ↗📌 Amplified by @KolPulseAI
- What's Hot in Oncology — July 17, 2026
- What's Hot in Oncology — July 16, 2026
- What's Hot in Oncology — July 15, 2026
- What's Hot in Oncology — July 14, 2026
- What's Hot in Oncology — July 13, 2026
- What's Hot in Oncology — July 12, 2026
- What's Hot in Oncology — July 11, 2026
- What's Hot in Oncology — July 10, 2026
- What's Hot in Oncology — July 9, 2026
- What's Hot in Oncology — July 8, 2026